Our core scientific assets, the Lipid-Antiviral-Conjugate Technology and the Chimerix Chemical Library provide us with a rich source for new drug leads.
In evaluating the compounds within the Chimerix Chemical Library, we have identified several unique classes of nucleoside analogues, including several extremely potent drug leads against hepatitis C virus (HCV). We plan to select a candidate for preclinical development, as well as additional promising back-up compounds. HCV is the primary cause of chronic liver disease in the U.S., accounting for up to 50 percent of cirrhosis, end-stage renal disease and liver cancer. An estimated 4.1 million Americans are believed to be infected with HCV.
We are also screening compounds to address influenza A and B, as well as dengue virus, malaria and tuberculosis.
Our pipeline is fueled by two proprietary sources derived from the innovations of renowned antiviral scientists. Our Lipid-Antiviral-Conjugate Technology was originally developed by Karl Hostetler, M.D., Professor of Medicines at the University of California, San Diego and a leading expert in the field of infectious disease. The Conjugate Technology is used to modify a drug molecule so that it mimics a naturally occurring phospholipid. Read More